Shares of Globus Medical rose after the company issued preliminary fourth-quarter sales numbers and a 2026 outlook that both beat analysts' expectations. The stock gained 10% to $99.74 in after-hours ...
GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback